In NSCLC models, Redin et al. have demonstrated a synergistic antitumor effect between dasatinib and anti-PD-1, with a reduction in the number of Tregs and an increase in CD4+ and CD8+ T cells. This evidence concerns the gene CD8A and non-small cell lung carcinoma.